We want to help patients swiftly and in the most efficient way. At the moment, very few drug innovations arrive in the clinic for patient benefit. Repurposing registered drugs is faster and more cost-efficient than de novo drug design. REPO-TRIAL aims to improve the efficacy and precision of drug repurposing by redefining diseases entirely mechanistically, as opposed to merely descriptive definitions by symptom or organ. To reach this goal, we will exploit the existing wealth of medical big data and use advanced algorithms and cutting edge in silico modelling. An in silico model that reliably predicts efficient repurposing will revolutionize medicine.
WHY IT MATTERS
Pharmaceutical research and development (R&D) field faces a serious crisis. Its efficacy, for example the approval of novel drugs, has decreased dramatically over time, despite an ever growing mountain of biological knowledge. At the same time, the costs of R&D have skyrocketed. In the United States, for example, the average cost until market entry of a new drug is now at 3.8 billion US Dollars. A key culprit for this crisis is an alarming disconnect between preclinical basic research and clinical trials.